Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Oncology

Decoding the Warning Signs: 10 Behaviour Changes Demanding Attention

Pets communicate through actions and it holds true for happiness as well as distress. Dr. Abhishek Choudhary, Veterinarian, Vetic, looks at 10 common behaviour changes that can signal illness, discomfort, or ageing-related issues in pets. He will also explain why prompt veterinary care is essential when you notice these signs…

Times Pets

Little Heroes: EU Parliament pays tribute to child cancer victims with Brussels art exhibition

Part of the European Parliament in Brussels has been transformed into a glowing artistic tribute space this week to display colourful paintings from the Children's Oncology Unit of Makareio Hospital in Cyprus

Euronews

Free HPV Vaccine for Girls What Parents Need to Know

Human Papillomavirus or HPV is a group of more than 100 related viruses, some of which are classified as high risk types because they can cause cancer. Persistent infection with high risk HPV strains, particularly HPV 16 and HPV 18, is responsible for the majority of cervical cancer cases globally.…

MyLifeXP

From analysis to the latest developments in health,
read the most diverse news in one place.

'Cuba's healthcare system is being pushed to the brink by US blockades,' says health minister

Cuba’s Health Minister says the country is headed to a catastrophic humanitarian crisis, saying the US blockade of oil on his country is rendering hospitals helpless and puts thousands of lives at risk.

Euronews

Who is Kashyap Patel? Indian-origin doctor wins prestigious NRI award Hind Rattan for transforming cancer care

Kashyap Patel, an Indian-origin physician, has been honored with the prestigious Hind Rattan Award for his two decades of work in community oncology. He is recognized for championing equitable access to high-quality cancer care, particularly for rural and underserved populations, and advocating for patient-centered treatment beyond major urban hospitals.

The Times of India

1 Under-$10 Stock Set to Surge as Much as 850% in 2026

Kura is a classic high-risk, high-reward biotech investment that has entered a vital growth phase.

Barchart

Exelixis Reports Solid Earnings—Are New Highs Back on the Table?

Exelixis beats earnings estimates as Cabometyx drives profits and zanzalintinib positions the biotech for a major oncology expansion

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most

Pfizer stock jumped after a strong earnings beat and positive GLP-1 data, but investors may be overlooking a powerful oncology and AI-driven growth story.

MarketBeat

'We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The winners always stand up again."

Fortune

A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

MarketBeat

Upcoming 2026 Medical Events for Healthcare Professionals

Discover the top medical conferences in 2026 for healthcare professionals. Plan your year of learning and networking.

inkl

Inside CTOAM's Precision Oncology Approach and Its Focus on Advanced Diagnostics With Individual Cancer Patients' Needs

At the core of CTOAM's work, Morand explains, is a precision oncology process that integrates multiple diagnostic tools into a single, coordinated pathway. The company supports tumor DNA and RNA sequencing, whole genome liquid biopsies for real-time monitoring, and advanced imaging, including PET-CT scans, depending on what each individual case…

International Business Times

Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for value investors in the coming year.

MarketBeat

This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell?

Not a collapse, just a pivot toward what matters most. Arcus Biosciences still has plenty of potential.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Cancer Early Symptoms You Shouldn't Ignore: A Powerful Oncology Awareness Guide

Discover key cancer early symptoms, boost oncology awareness, and learn when to seek medical help to support earlier detection, timely diagnosis, and better treatment outcomes.

Barchart

This Oncology Stock Just Hit New All-Time Highs

Revolution Medicines (RVMD) is trading at fresh all-time highs. RVMD exhibits strong technical momentum with a 100% technical “Buy” opinion from Barchart. Shares are up nearly 60% over the past year. Wall Street analysts are overwhelmingly bullish on RVMD, although sentiment is mixed across other platforms. Today’s Featured Stock Valued...

Barchart

This Undiscovered Biotech Stock Has Quintupled in a Year and Just Hit New Highs

Burning Rock Biotech (BNR) , a precision oncology company from China, has shown exceptional technical momentum and price appreciation. BNR has surged 405% over the past year, hitting a 2-year high on Wednesday. Despite strong technicals, BNR is a highly speculative and risky stock. Today’s Chart of the Day is...

AAP

Oncology company reports promising cancer find

Shares in Kazia Therapeutics have risen more than 50 per cent after its drug candidate appeared to successfully treat a woman with stage-four breast cancer.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

‘It would be cheaper if I died:’ Cancer patients are battling insurance companies for their lives

IN FOCUS: EXCLUSIVE: Cancer patients, oncologists and advocates tell Rhian Lubin why the US health insurance system needs urgent reform, and is risking the lives of Americans fighting the disease

Benzinga

Moderna Q3 2025 Earnings Call Transcript

Moderna, Inc (NASDAQ:MRNA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. MRNA is building positive momentum. Watch the momentum here This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visithttps://www.benzinga.com/apis/for a consultation. Operator…

inkl

Promising Therapies Extend Survival in Stage 4 Breast Cancer

Stage 4 breast cancer is also known as metastatic breast cancer. As the research evidence reports, it is the most advanced form of the disease.

Barchart

1 Growth Stock Under $100 to Buy Before It Soars

This biotech under $100 looks like a growth opportunity worth grabbing before it soars.

Benzinga

Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial

Kura Oncology, Inc. (NASDAQ:KURA) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Kirin.

Benzinga

Whitehawk Therapeutics Stock Is Trading Higher Thursday: What's Going On?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI Inc (NASDAQ:TEM) to support the development of its oncology pipeline.

Benzinga

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations

Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (ex20ins) or uncommon non-ex20ins EGFR mutations.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Parliament

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.